Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Director Daniel J Hennessy sold 10,828 shares of Innventure, Inc. (INV:INV) on October 9, 2025, at prices ranging from $5.04 to $5.28, netting approximately $56,413. The transaction comes as the stock trades near its 52-week low of $3.00, having declined over 76% year-to-date. Following the transaction, Hennessy directly owns 1,173,745 shares of the company. According to InvestingPro analysis, the company currently shows weak financial health with concerning cash burn rates.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. For deeper insights into insider trading patterns and 15+ additional key metrics, check out the comprehensive research available on InvestingPro.
In other recent news, Innventure Inc. reported its second-quarter 2025 earnings, highlighting a notable increase in revenue. This growth was largely attributed to the performance of its Excelsius division and ESG fund management. Additionally, Innventure completed a private placement, raising approximately $9.75 million in gross proceeds through the sale of common stock and Series A warrants. In a separate transaction, Accelsius Holdings LLC, a subsidiary of Innventure, received a $25 million investment from Johnson Controls. This investment is part of a strategic move by Johnson Controls to enhance energy-efficient cooling solutions in data centers. Furthermore, Innventure’s Audit Committee approved the dismissal of BDO USA as its independent auditor, replacing it with WithumSmith+Brown. The decision follows BDO’s audit reports, which included an explanatory paragraph expressing concerns about the company’s ability to continue as a going concern. These developments reflect Innventure’s ongoing strategic and financial activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.